Spotlight On... Intuitive touts study results on robotic surgery use for hysterectomies; Masimo to integrate device data into EMRs; Vital Connect, physIQ partner on remote patient monitor; and more...

Intuitive Surgical ($ISRG) touted a study which found robotic-assisted benign hysterectomy results in improved outcomes compared to traditional surgical techniques. "It's long been clear that minimally invasive hysterectomy can help reduce complications and speed recovery. But past studies comparing open and minimally invasive approaches compared less experienced robotic-assisted surgeons with colleagues in other approaches," said Dr. Peter Lim of The Center of Hope, Renown Regional Medical Center in Reno, NV. "This study is designed to compare only the outcomes of similarly experienced surgeons, regardless of surgical approach, which provides a much more accurate picture of comparative effectiveness." More

@FierceMedDev: Walgreens plots emergency exit from partnership with Theranos: FT. More | Follow @FierceMedDev

@EmilyWFierce: UPDATED: Zepatier beats Harvoni, Sovaldi in hep C clinical-data safety showdown: Advera Health Analytics. FiercePharma story | Follow @EmilyWFierce

> Masimo ($MASI) has debuted server-based software for integrating medical device data into electronic medical records, dubbed Iris Gateway. More

> BD ($BDX) received a CE mark for its next-gen blood separation tech, BD Vacutainer Barricor, that's expected to improve sample quality and lab efficiency. More

> Vital Connect and physIQ have partnered to develop a 510(k) cleared wearable remote patient device that incorporates personalized, machine learning analytics. More

Biotech News

@FierceBiotech: PTC: With no evidence of Duchenne MD efficacy, FDA barred regulators' doors to ataluren. Article | Follow @FierceBiotech

@JohnCFierce: Does Roche's IL-13 setback in PhIII signal similar trouble ahead for AstraZeneca? Story | Follow @JohnCFierce

@DamianFierce: Hillary Clinton: enemy of Gut Guy. Watch | Follow @DamianFierce

> Savara raises $20M to push its inhaled antibiotic into Phase III. News

> ProMetic raises $30 million. Item

> Ipsen bets up to $855M on Exelixis' once-failed cancer drug. Article

Pharma News

@FiercePharma: FDA swats down Teva's EpiPen copy, putting Mylan in cruise control. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Teva plots global rebrand as it prepares to join hands with Allergan's generics unit. Article | Follow @CarlyHFierce

> Big vials mean bigger revenue for cancer drugmakers, wasted billions for payers and patients. More

> Horizon Pharma joins Valeant in DOJ's specialty pharmacy probe. Story

> FDA swats down Teva's EpiPen copy, putting Mylan in cruise control. Article

Pharma Manufacturing News

> Lupin plans to add plant in Japan. News

> Potentially tainted heparin from China uncovered by French regulators. Report

> CMO helps TxCell move forward with clinical supplies after pilot plant closed. Item

> Novartis' Alcon unit recalls eye drop vials over questionable sterility. Story

> New plant to be online in UAE by end of 2016. Article

Pharma Asia News

> Bayer incoming CEO highlights OTC challenges in China in three-way integration. More

> China FDA prioritizes innovative drugs as 2015 approvals dipped. Story

> China's Mindray gets shareholder nod for reduced management-led buyout. Report

> China FDA chief Bi updates press on quality crackdown. More

> South Korea approved more clinical trials in 2015. Article

Drug Delivery News

> Israel's PolyPid raises $22M for its extended-release antibiotic to prevent surgical site infections. Item

> Sweden's Redwood gets private placement for its sustained-release dry eye disease candidate. Story

> AstraZeneca funds 'robotic pill' company Rani Therapeutics in pursuit of oral biologics. Article

> J&J, ViiV tout trial showing their long-acting HIV-fighting injectables are comparable to daily pills. More

> U.K.-Netherlands startups join forces for robot-assisted gene delivery to the eye. Article

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.